Lifebloom, founded in 2019, has developed an integrated therapy centered on the Lifebloom One exoskeleton, coupled with gait analysis systems, a care platform and validated rehabilitation protocols. The company says its approach enables patients who cannot walk alone to recover autonomous gait and substantially increase daily time spent standing, with clinical validation at AP‑HP Pitié‑Salpêtrière showing recovery of autonomous walking and a sixfold increase in standing time in post-stroke patients. Since its public launch at the end of 2024, Lifebloom reports testimonials from more than 10,000 patients, caregivers and clinicians. Current plans include industrializing production, deploying dedicated "Units of the Walk" in hospitals, conducting further clinical and economic studies, and building logistics for at-home continuation of therapy. The recent €8M raise (equity plus France 2030 grants) will fund scaling to 30 sites, expansion of operations, and preparation for broader European deployment.

Total raised

$9M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2026